top of page
Search Results

108 items found for "ovarian cancer"

  • Fentanyl activates ovarian cancer and alleviates chemotherapy-induced toxicity via opioid...

    September 2022 Fentanyl activates ovarian cancer and alleviates chemotherapy-induced toxicity via opioid cancer patients for pain management. Although increasing evidence has suggested the direct role of fentanyl on cancer, little is known on the effect of fentanyl on ovarian cancer cells. Methods Proliferation, migration and apoptosis assays were performed in ovarian cancer cells after

  • Cell-Type-Specific Effects of the Ovarian Cancer G-Protein Coupled Receptor (OGR1) on Inflammation..

    September 2022 Cell-Type-Specific Effects of the Ovarian Cancer G-Protein Coupled Receptor (OGR1) on Here, we report that the Ovarian Cancer G-Protein Coupled Receptor1 (OGR1 or GPR68) has dual roles in

  • 📰 GPCR Weekly News, June 17 to 23, 2024

    GPCRs in Oncology and Immunology Regulator of G protein signaling 16 restrains apoptosis in colorectal cancer cancer cells by targeting PAR-1 G protein-coupled receptors related to autoimmunity in postural orthostatic cancer prognosis GprC of the nematode-trapping fungus Arthrobotrys flagrans activates mitochondria and reprograms fungal cells for nematode hunting Role and recent progress of P2Y12 receptor in cancer development immunotherapy: a Society for Immunotherapy of Cancer (SITC) strategic vision Structural and Molecular

  • 📰 GPCR Weekly News, July 10 to 16, 2023

    GPCRs in Oncology and Immunology Ovarian cancer G protein-coupled receptor 1 (OGR1) deficiency exacerbates Colorectal cancer incidence trends in Golestan, Iran: An age-period-cohort analysis 2004-2018.

  • Molecular basis for variations in the sensitivity of pathogenic rhodopsin variants to 9-cis-retinal

    Though most of these variants exhibit a loss of function, the molecular defects caused by these underlying scanning to quantitatively compare the plasma membrane expression of 123 known pathogenic rhodopsin variants We identify 69 retinopathy variants, including 20 previously uncharacterized variants, that exhibit diminished Of these apparent class II variants, 67 exhibit a measurable increase in expression in the presence of Nevertheless, estimates from computational modeling suggest that many of the least sensitive variants

  • 📰 GPCR Weekly News, August 14 to 20, 2023

    Vladimir Katanaev and colleagues identified compromised GPCR signaling in cancer cells using improved MRGPRX1 Improved approaches to channel capacity estimation discover compromised GPCR signaling in diverse cancer ADGRF1) activation PAXIP1-AS1 is associated with immune infiltration and predicts poor prognosis in ovarian cancer A virally encoded GPCR drives glioblastoma through feed-forward activation of the SK1-S1P1 signaling Therapeutics' latest science paper was published by the American College of Clinical Pharmacology Sosei and Cancer

  • 📰 GPCR Weekly News, July 17 to July 23, 2023

    A corazonin G protein-coupled receptor gene in the tick Ixodes scapularis yields two splice variants, Industry News Exscientia Initiates Prospective Observational Study in Ovarian Cancer. Undrugged GPCR Target in Four Months Cumulus Oncology and Leadxpro collaborate on small molecules targeting cancer-focused

  • Cancer Research UK and Sosei Heptares sign agreement to advance cancer immunotherapy candidate ...

    July 2022 Cancer Research UK and Sosei Heptares sign agreement to advance cancer immunotherapy candidate into clinical trials " HTL0039732 is a novel EP4 antagonist with potential to treat a wide range of cancers company and world-leader in GPCR1-focused structure-based drug design (SBDD) and development, an d Cancer Research UK , the world’s largest private funder of cancer research, today announce the signing of an agreement to bring Sosei Heptares ’ cancer immunotherapy drug candidate into a first-in-human trial.

  • Dr. GPCR University registration is now open! Secure your spot now!

    remodeling GPCRs in Oncology and Immunology Unveiling G-protein coupled receptors as potential targets for ovarian cancer nanomedicines: from RNA sequencing data analysis to in vitro validation Signaling by Neutrophil

  • The expression and clinical significance of GPR39 in colon cancer

    September 2022 " Background: Colorectal cancer is the third most common cancer and requires more prognostic The clinical significance of GPR39 in colon cancer has never been reported. Materials: In our study, we compared GPR39 expression between colon cancers and tumor-adjacent tissues by retrieving TCGA data and detected the expression of GPR39 in colon cancers with qPCR and immunohistochemistry

  • 📰 GPCR Weekly News, August 28 to September 3, 2023

    inside and back again: the lysophosphatidic acid-CCN axis in signal transduction NPFF stimulates human ovarian cancer cell invasion by upregulating MMP-9 via ERK1/2 signaling CCR7 acts as both a sensor and a sink

  • 📰 GPCR Weekly News, April 15 to 21, 2024

    Immunology Deciphering a GPCR-lncRNA-miRNA Nexus: Identification of an Aberrant Therapeutic Target in Ovarian Cancer Methods & Updates in GPCR Research Alared: Solvatochromic and Fluorogenic Red Amino Acid for

  • Regulators of G-protein signaling: essential players in GPCR signaling

    has been implicated in a range of diseases, including cardiovascular disease, pain, hypertension, and cancer While in cancer, RGS proteins are involved in regulating cell proliferation and survival[8]. Y., et al., Identification of a five-gene signature of the RGS gene family with prognostic value in ovarian cancer.

  • 📰 GPCR Weekly News, January 22 to 28, 2024

    parahaemolyticus Involvement of Protease-Activated Receptor2 Pleckstrin Homology Binding Domain in Ovarian Cancer: Expression in Fallopian Tubes and Drug Design Structural and Molecular Insights into GPCR Function

  • Exploiting Dependence of Castration-Resistant Prostate Cancer on the Arginine Vasopressin ...

    September 2022 Exploiting Dependence of Castration-Resistant Prostate Cancer on the Arginine Vasopressin Signaling Axis by Repurposing Vaptans "Men with advanced prostate cancer are treated by androgen deprivation therapy but the disease recurs as incurable castration-resistant prostate cancer (CRPC), requiring new Interrogation of prostate cancer patient sample data revealed that coexpression of AVPR1A and AVPR2 is

  • The Bile Acid Membrane Receptor TGR5 in Cancer: Friend or Foe?

    regulating proliferation, inflammation, adhesion, migration, insulin release, muscle relaxation, and cancer Several recent studies have demonstrated that TGR5 exerts inconsistent effects in different cancer cells

  • High GPER expression in triple-negative breast cancer is linked to pro-metastatic pathways and...

    September 2022 High GPER expression in triple-negative breast cancer is linked to pro-metastatic pathways and predicts poor patient outcomes "Triple-negative breast cancer (TNBC) is a particularly aggressive It is generally considered that TNBC is an estrogen-independent breast cancer, while a new estrogen receptor

  • GASP1 enhances malignant phenotypes of breast cancer cells and decreases their response to...

    September 2022 GASP1 enhances malignant phenotypes of breast cancer cells and decreases their response However, its biological function and underlying molecular mechanism in breast cancer have not been clearly Here, we demonstrated that GASP1 was highly expressed in breast cancers, and patients harboring altered Functional studies showed that GASP1 knockout significantly suppressed malignant properties of breast cancer Collectively, this study demonstrates that GASP1 enhances malignant behaviors of breast cancer cells

  • Propranolol: A “Pick and Roll” Team Player in Benign Tumors and Cancer Therapies

    September 2022 "Research on cancer therapies focuses on processes such as angiogenesis, cell signaling last decade, increasing evidence of its antitumoral properties in more than a dozen different types of cancer

  • PAR-Induced Harnessing of EZH2 to β-Catenin: Implications for Colorectal Cancer

    involved in a wide array of physiological and disease functions, yet knowledge of their role in colon cancer reveal that PAR-induced post-transcriptional regulation of β-catenin is centrally involved in colon cancer

  • GPR108 is required for gambogic acid inhibiting NF-κB signaling in cancer

    targets for drug discovery, however, their role in oncology is underappreciated and GPCR-based anti-cancer identified GPR108, a GPCR protein described in innate immune system, is a potential therapeutic target of cancer Depletion of GPR108 dramatically inhibited the survival of various cancers. Overall, our findings supported GPR108 as a promising therapeutic target of cancer, and provided a small molecule inhibitor GA directly and selectively targeting GPR108 for cancer therapy."

  • MSX-122: Is an effective small molecule CXCR4 antagonist in cancer therapy?

    August 2022 "Chemokines, a subgroup of cytokines along with their receptors, are involved in various biologic processes and regulation of a wide range of immune responses in different physiologic and pathologic states such as tissue repair, infection, and inflammation. C-X-C motif chemokine receptor 4 (CXCR4), a G-protein-coupled receptor (GPCR), has one identified natural ligand termed stromal-derived factor-1(SDF-1 or CXCL12). Evidence demonstrated that the ligation of SDF-1 to CXCR4 initiates several intracellular signaling pathways, regulating cell proliferation, survival, chemotaxis, migration, angiogenesis, adhesion, as well as bone marrow (BM)-resident cells homing and mobilization. Additionally, CXCR4 is expressed by tumor cells in blood malignancies and solid tumors." Read more at the source #DrGPCR #GPCR #IndustryNews

  • Anatomy of a partnership: Cancer Research UK teams up with Sosei Heptares

    August 2022 "August 10, 2022 Cancer Research UK is working with global biopharma Sosei Heptares on a treatment they hope will bring immunotherapy benefits to new cancer types. Cancer Research UK , a charity dedicated to funding lifesaving oncology research, spent £388 million on cancer research last fiscal year.

  • Identification of A2BAR as a potential target in colorectal cancer using novel fluorescent GPCR...

    October 2022 Identification of A2BAR as a potential target in colorectal cancer using novel fluorescent targeted in a wide range of diseases, but few therapies have been directed against GPCRs in the field of cancer Here, using colorectal cancer (CRC) as a model, we explored the gene expression of a panel of GPCRs in We selected the adenosine receptor 2B (A2BAR), specifically expressed in cancer cell lines compared with

  • Deciphering the signaling mechanisms of β-arrestin1 and β-arrestin2 in regulation of cancer cell...

    August 2022 Deciphering the signaling mechanisms of β-arrestin1 and β-arrestin2 in regulation of cancer physiological processes, these activities are also involved in the onset and progression of various cancers primary emphasis on the signaling processes which underlie the mechanism of β-arrestins in the onset of cancer processes has important implications for understanding the therapeutic intervention and treatment of cancer

  • Novel Driver Strength Index highlights important cancer genes in TCGA PanCanAtlas patients

    September 2022 "Background Cancer driver genes are usually ranked by mutation frequency, which does with few driver mutations overall, because these few mutations should be strong enough to initiate cancer

  • Deciphering the signaling mechanisms of β-arrestin1 and β-arrestin2 in regulation of cancer cell...

    November 2022 Deciphering the signaling mechanisms of β-arrestin1 and β-arrestin2 in regulation of cancer physiological processes, these activities are also involved in the onset and progression of various cancers primary emphasis on the signaling processes which underlie the mechanism of β-arrestins in the onset of cancer processes has important implications for understanding the therapeutic intervention and treatment of cancer

  • Lack of Oestrogen Receptor Expression in Breast Cancer Cells Does Not Correlate with Kisspeptin...

    September 2022 Lack of Oestrogen Receptor Expression in Breast Cancer Cells Does Not Correlate with Kisspeptin Signalling and Migration "Kisspeptin is an anti-metastatic mediator in many cancer types, acting through However, controversy remains regarding its role in breast cancer since both pro- and anti-metastatic In KISS1R overexpressing triple-negative breast cancer (TNBC) cells, stimulation has been associated

bottom of page